Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill help shed excess weight? a new trial investigates

NCT ID NCT07770841

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This Phase 3 trial is investigating whether lower doses of oral semaglutide can help adults with overweight or obesity lose weight. Participants will take either the medication or a placebo daily, and researchers will measure the percentage change in body weight. The goal is to find the most effective lower dose for weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (taken orally)
What this could lead to
If successful, this could provide a convenient, lower-dose oral option for weight management in people with overweight or obesity.
What could go wrong
This is an early-stage trial, so results may not confirm effectiveness or safety. Side effects and individual variability could limit its impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. ≥ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    62 sites in 10 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AIPSMC - DiMed EOOD

    RECRUITING

    Haskovo, 6300, Bulgaria

  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus

    RECRUITING

    Aarhus N, 8200, Denmark

  • Anima Research Center

    RECRUITING

    Alken, 3570, Belgium

  • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit

    RECRUITING

    Marousi, 15125, Greece

  • Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department

    RECRUITING

    Peristeri, 121 31, Greece

  • Athleticomed Sp. z o.o.

    NOT_YET_RECRUITING

    Bydgoszcz, 85-752, Poland

  • CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques

    RECRUITING

    Vénissieux, 69200, France

  • CPE Bola Azul_Endocrinología y Nutrición

    RECRUITING

    Almería, 04009, Spain

  • CTC GoCo Mölndal

    RECRUITING

    Mölndal, 431 53, Sweden

  • CTC Stockholm

    RECRUITING

    Stockholm, 171 64, Sweden

  • Care Access Polska Sp. Z o.o.

    NOT_YET_RECRUITING

    Warsaw, 00-719, Poland

  • Cedar Health Research

    RECRUITING

    Dallas, Texas, 75251, United States

  • Centrum Zdrowia Metabolicznego Paweł Bogdański

    RECRUITING

    Poznan, 60-589, Poland

  • City Hospital Kliniki Monoprosopi I.K.E.

    RECRUITING

    Kalamata, 24100, Greece

  • Clínica Gaias Santiago

    RECRUITING

    Santiago de Compostela, 15702, Spain

  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología

    RECRUITING

    Seville, 41003, Spain

  • Clínica Palacios Madrid

    RECRUITING

    Madrid, 28009, Spain

  • Corvallis Clinic PC Clinical Research Department

    RECRUITING

    Corvallis, Oregon, 97330-3737, United States

  • DCC 1 Velingrad EOOD

    RECRUITING

    Velingrad, 4600, Bulgaria

  • DCC Neoklinik EAD

    RECRUITING

    Sofia, 1408, Bulgaria

  • ERG Holding Company, LLC / Evolution Research Group, LLC

    RECRUITING

    Delray Beach, Florida, 33445, United States

  • ERG Holding Company, LLC / Evolution Research Group, LLC

    RECRUITING

    Fort Myers, Florida, 33192, United States

  • East West Med Res Inst

    RECRUITING

    Honolulu, Hawaii, 96814, United States

  • Enheten för Kliniska Studier (EKS), Örebro

    RECRUITING

    Örebro, 703 62, Sweden

  • FutureMeds Sp. z o.o.

    RECRUITING

    Warsaw, 03-291, Poland

  • Gentofte Hospital - Center for Klinisk Metabolisk Forskning

    RECRUITING

    Hellerup, 2900, Denmark

  • Gierach-Med

    RECRUITING

    Bygdoszcz, 85-796, Poland

  • H. Infanta Luisa_Endocrino y Obesidad

    RECRUITING

    Seville, 41010, Spain

  • HU de Fuenlabrada_Endocrinología

    NOT_YET_RECRUITING

    Fuenlabrada, Madrid, 28042, Spain

  • Headlands Research California, LLC

    RECRUITING

    Escondido, California, 92025, United States

  • Hosp. Vithas Sevilla_Endocrino y Nutrición

    RECRUITING

    Castilleja de la Cuesta, 41950, Spain

  • Hospital Naval Ferrol

    RECRUITING

    Ferrol, 15405, Spain

  • Hôpital Privé La Louvière_Service de chirurgie

    RECRUITING

    Lille, 59800, France

  • Hôpital Privé Saint Martin_Service de chirurgie digestive

    RECRUITING

    Caen, 14000, France

  • IPMC - Dr. Elizabeta Dimitrova

    NOT_YET_RECRUITING

    Petrich, 2850, Bulgaria

  • Imelda

    RECRUITING

    Bonheiden, 2820, Belgium

  • Jedidiah Clinical Research

    RECRUITING

    Tampa, Florida, 33619, United States

  • Jubilee Clinical Research, Inc.

    RECRUITING

    Las Vegas, Nevada, 89106, United States

  • KORMONT

    RECRUITING

    Kluisbergen, 9690, Belgium

  • Kresmed Sp. z o. o.

    NOT_YET_RECRUITING

    Bialystok, 15-481, Poland

  • L-MARC Research Center

    RECRUITING

    Louisville, Kentucky, 40213, United States

  • LES HOPITAUX DE CHARTRES_HOPITAL LOUIS PASTEUR_Service d'endocrinologie

    RECRUITING

    Le Coudray, 28630, France

  • Los Angeles Institute for Metabolic Research

    RECRUITING

    Los Angeles, California, 90015, United States

  • MHAT Hadzhi Dimitar OOD

    RECRUITING

    Sliven, 8800, Bulgaria

  • Medical Center Zdrave Lom EOOD

    RECRUITING

    Lom, 3600, Bulgaria

  • NBR Polska Tomasz Klodawski

    RECRUITING

    Warsaw, 00-710, Poland

  • National Research Institute - Huntington Park

    RECRUITING

    Huntington Park, California, 90255, United States

  • NextHealth S.A. - Department of Endocrinology, Metabolism & Diabetes

    RECRUITING

    Thessaloniki, 54635, Greece

  • Praktijk Dokters van Nederhoven

    RECRUITING

    Zwijndrecht, 3334 SB, Netherlands

  • Progress Clinical Research Amsterdam

    RECRUITING

    Amsterdam, 1081 GN, Netherlands

  • Progress Clinical Research Zwolle

    RECRUITING

    Zwolle, 8025 AZ, Netherlands

  • Regionshospitalet Gødstrup, Hjertesygdomme

    RECRUITING

    Herning, 7400, Denmark

  • Santa Sp. z o.o.

    NOT_YET_RECRUITING

    Lodz, 90-302, Poland

  • Selma Medical Associates

    RECRUITING

    Winchester, Virginia, 22601-3834, United States

  • Spartanburg Medical Research

    RECRUITING

    Spartanburg, South Carolina, 29303, United States

  • StudyMetrix Research LLC

    RECRUITING

    City of Saint Peters, Missouri, 63303, United States

  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department

    RECRUITING

    Thessaloniki, 57001, Greece

  • UPA Ctr Weight and Eating Dis

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • UZ Brussel - Universitair Ziekenhuis Brussel

    RECRUITING

    Brussels, 1090, Belgium

  • Uni of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35296, United States

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, 9000, Belgium

  • Velocity Nova Sp. z o.o.

    RECRUITING

    Staszów, 28-200, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.